Andrew D Weinberg
Overview
Explore the profile of Andrew D Weinberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
3054
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A, et al.
Cell
. 2023 Mar;
186(7):1432-1447.e17.
PMID: 37001503
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of the immune system may eliminate escape variants....
2.
Duhen R, Beymer M, Jensen S, Abbina S, Abraham S, Jain N, et al.
Front Immunol
. 2022 Oct;
13:896310.
PMID: 36238275
To prevent SARS-CoV-2 infections and generate long-lasting immunity, vaccines need to generate strong viral-specific B and T cell responses. Previous results from our lab and others have shown that immunizations...
3.
Duhen R, Fesneau O, Samson K, Frye A, Beymer M, Rajamanickam V, et al.
J Clin Invest
. 2022 Apr;
132(12).
PMID: 35439168
CD4+ Th cells play a key role in orchestrating immune responses, but the identity of the CD4+ Th cells involved in the antitumor immune response remains to be defined. We...
4.
Duhen R, Ballesteros-Merino C, Frye A, Tran E, Rajamanickam V, Chang S, et al.
Nat Commun
. 2021 Feb;
12(1):1047.
PMID: 33594075
Despite the success of checkpoint blockade in some cancer patients, there is an unmet need to improve outcomes. Targeting alternative pathways, such as costimulatory molecules (e.g. OX40, GITR, and 4-1BB),...
5.
van den Bulk J, Verdegaal E, Ruano D, Ijsselsteijn M, Visser M, van der Breggen R, et al.
Genome Med
. 2020 Jan;
11(1):87.
PMID: 31888734
Background: The efficacy of checkpoint blockade immunotherapies in colorectal cancer is currently restricted to a minority of patients diagnosed with mismatch repair-deficient tumors having high mutation burden. However, this observation...
6.
Polesso F, Sarker M, Weinberg A, Murray S, Moran A
J Immunol
. 2019 Aug;
203(7):2011-2019.
PMID: 31434709
OX40 is a costimulatory molecule from the TNFR family. In mice, it is expressed on Foxp3 regulatory T cells (Tregs) constitutively and on conventional CD4 (Tconv) and CD8 T cells...
7.
Hoffmann P, Hoffmann F, Premeaux T, Fujita T, Soprana E, Panigada M, et al.
Front Oncol
. 2019 Aug;
9:720.
PMID: 31428586
Malignant Mesothelioma (MM) is a rare and highly aggressive cancer that develops from mesothelial cells lining the pleura and other internal cavities, and is often associated with asbestos exposure. To...
8.
Polesso F, Weinberg A, Moran A
Cancer Immunol Res
. 2018 Dec;
7(2):269-281.
PMID: 30563828
The protective capability of tumor antigen-specific T cells is regulated by costimulatory and inhibitory signals. Current approaches in cancer immunotherapy seek to restore the function of unresponsive T cells by...
9.
Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda N, et al.
Nat Commun
. 2018 Jul;
9(1):2724.
PMID: 30006565
Identifying tumor antigen-specific T cells from cancer patients has important implications for immunotherapy diagnostics and therapeutics. Here, we show that CD103CD39 tumor-infiltrating CD8 T cells (CD8 TIL) are enriched for...
10.
Bell R, Gough M, Seung S, Jutric Z, Weinberg A, Fox B, et al.
Oral Oncol
. 2017 Feb;
66:e3.
PMID: 28202215
No abstract available.